IPO | Biotech and Money

One Year on from IPO: Motif Bio’s Commercialisation Route

Graham Lumsden, CEO of Motif Bio, talks to Biotech and Money about the commercialisation route of Motif Bio. Graham also presents his further non-clinical achievements of the last 12 month after IPO…

March 2016 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. The March issue is the second of 6 bi-monthly publications in 2016 aimed at providing insight, foresight…

Growth through commercialised tech and acquisitions

Biotech and Money had the opportunity to speak to Neil Campbell of Helomics about growth through commercialised tech and acquisitions. Neil Campbell serves as President and CEO of Helomics™. He is…

4 things I learned from Eddy Littler, CEO of Domainex

Biotech and Money recently had the opportunity to catch up with Eddy Littler, CEO of polymath biotech Domainex. With fingers in several academic pies, Domainex takes nurturing and funding the…

Life science IPOs: listing in UK or US

The decision to take a company public is never taken lightly. For life science companies, however, that decision is further complicated by deciding where to list? Life science IPOs are back…

Turning the tide: attracting transatlantic biotech issuers to AIM

London Stock Exchange is a diversified international exchange Group that sits at the heart of the world’s financial community. Through its markets, the Group offers international business, and investors, unrivalled access to Europe’s…

The Californian biotech who brought a $100m IPO to UK shores

Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development. The company’s platform is the first systematic, computationally-driven solution to…

View of an active private life science investor

In March, Jon Moulton increased his shareholding in Redx Pharma as the biotech company successfully completed it’s IPO on London’s AIM. Jon has long experience of turnarounds, having invested in…

From developing highly differentiated ‘best-in-class’ new drugs to IPO

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and infection. By improving the characteristics of existing drug classes…

Using conformational design to target a $9bn therapeutic market

C4X Discovery, a Manchester-based, AIM-listed Company which uses an NMR-based technique to optimise drug discovery, possess a unique drug discovery technology has the potential to cut preclinical development times and cost by…